Understanding and harnessing the graft-versus-leukaemia effect

British Journal of Haematology

Volumn 142, Issue 6, 2008, Pages 877-888

  Barrett, A John ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Bone marrow transplantation; Graft versus leukaemia; Leukaemia

Indexed keywords

AMSACRINE; CANCER VACCINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; FLUDARABINE; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; LENALIDOMIDE; LYMPHOCYTE ANTIBODY; MONTANIDE ISA 51; PEPTIDE VACCINE;

ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADD ON THERAPY; ADOPTIVE TRANSFER; ALLOIMMUNITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER SURVIVAL; CANCER THERAPY; CELL FUNCTION; CHEMOPROPHYLAXIS; CHRONIC MYELOID LEUKEMIA; CLINICAL STUDY; DONOR; DONOR SELECTION; DRUG DOSE COMPARISON; DRUG MEGADOSE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LEUKEMIA RELAPSE; LOW DRUG DOSE; LYMPHOCYTE; MEMORY T LYMPHOCYTE; MOLECULAR DYNAMICS; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REVIEW; STEM CELL TRANSPLANTATION; SUICIDE GENE THERAPY; T CELL DEPLETION; T LYMPHOCYTE; TARGET CELL;

BONE MARROW TRANSPLANTATION; CANCER VACCINES; GRAFT VS LEUKEMIA EFFECT; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION CONDITIONING;

EID: 50049084370     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07260.x     Document Type: Review

References (99)

1. Aleya, E.P., Kim, H.T., Ho, V., Cutler, C., DeAngelo, D.J., Stone, R., Ritz, J., Antin, J.H. Soiffer, R.J. (2006) Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biology of Blood and Marrow Transplantation, 12, 1047 1055.
2. Alpdogan, O., Eng, J.M., Muriglan, S.J., Willis, L.M., Hubbard, V.M., Tjoe, K.H., Terwey, T.H., Kochman, A. van den Brink, M.R. (2005) Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood, 105, 865 873.
3. Amrolia, P.J., Muccioli-Casadei, G. Huls, H. (2006) Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplant. Blood, 108, 1797 1808.
4. Andre-Schmutz, I., Le Deist, F., Hacein-Bey-Abina, S., Vitetta, E., Schindler, J., Chedeville, G., Vilmer, E., Fischer, A. Cavazzana-Calvo, M. (2002) Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet, 360, 130 137.
5. Bacigalupo, A., Vitale, V., Corvo, R., Barra, S., Lamparelli, T., Gualandi, F., Mordini, N., Berisso, G., Bregante, S., Raiola, A.M., Van Lint, M.T. Frassoni, F. (2000) The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation. British Journal of Haematology, 108, 99 104.
6. Barnes, D.W.H. Loutit, J.F. (1956) Treatment of murine leukemia with X-rays and homologous marrow. British Medical Journal, 2, 626 627.
7. Baron, F. Beguin, Y. (2002) Preemptive cellular immunotherapy after T-cell-depleted allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 8, 351 359.
8. Baron, F. Sandmaier, B.M. (2006) Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia, 20, 1690 1700.
9. Barrett, J. (2006) Improving outcome of allogeneic stem cell transplantation by immunomodulation of the early post-transplant environment. Current Opinion in Immunology, 18, 592 598.
10. Barrett, A.J. Rezvani, K. (2007) Translational mini-review series on vaccines: peptide vaccines for myeloid leukaemias. Clinical and Experimental Immunology, 148, 189 198.
11. Barrett, A.J. Savani, B. (2006) Stem cell transplantation with reduced intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia, 20, 1661 1672.
12. Barrett, A.J., Locatelli, F., Treleaven, J.G., Gratwohl, A., Szydło, R. Zwaan, F.E. (1991) Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia Working Party. British Journal of Haematology, 79, 567 574.
13. Barrett, A.J., Ringden, O., Zhang, M.-J., Bashey, A., Cahn, J.Y., Cairo, M.S., Gale, R.P., Gratwohl, A., Locatelli, F., Martino, R., Schultz, K.R. Tiberghien, P. (2000) Effect of nucleated marrow cell dose on relapse and survival in identical twin transplants for leukemia. Blood, 95, 3323 3327.
14. Berger, C., Jensen, M.C., Lansdorp, P.M., Gough, M., Elliot, C. Riddell, S.R. (2008) Adoptive transfer of effector CD8 T cells derived from central memory cells establishes persistent T cell memory in primates. Journal of Clinical Investigation, 118, 294 305.
15. Bocchia, M., Gentili, S., Abruzzese, E., Fanelli, A., Iuliano, F., Tabilio, A., Amabile, M., Forconi, F., Gozzetti, A., Raspadori, D., Amadori, S. Lauria, F. (2005) Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet, 365, 657 662.
16. Bondanza, A., Valtolina, V., Magnani, Z., Ponzoni, M., Fleischhauer, K., Bonyhadi, M., Traversari, C., Sanvito, F., Toma, S., Radrizzani, M., La Seta-Catamancio, S., Ciceri, F. Bordignon, C. (2006) Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood, 107, 1828 1836.
17. Brooks, A.G., Boyington, J.C. Sun, P.D. (2000) Natural killer cell recognition of HLA class I molecules. Reviews in Immunogenetics, 2, 433 448.
18. Champlin, R., Passweg, J., Zhang, M.J., Rowlings, P.A., Pelz, C.J., Atkinson, K.A., Barrett, A.J., Cahn, J.Y., Drobyski, W.R., Gale, R.P., Goldman, J.M., Gratwoh, I.A., Gordon-Smith, E.C., Henslee-Downey, P.J., Herzig, R.H., Klein, J.P., Marmont, A.M., O'Reilly, R.J., Ringdén, O., Slavin, S., Sobocinski, K.A., Speck, B., Weiner, R.S. Horowitz, M.M. (2000) T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood, 95, 3996 4003.
19. Chang, D.H., Liu, N., Klimek, V., Hassoun, H., Mazumder, A., Nimer, S.D., Jagannath, S. Dhodapkar, M.V. (2006) Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood, 108, 618 621.
20. Chen, B.J., Cui, X., Liu, C. Chao, N.J. (2002) Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood, 99, 3083 3088.
21. Chen, C., Busson, M., Rocha, V., Appert, M.L., Lepage, V., Dulphy, N., Haas, P., Socié, G., Toubert, A., Charron, D. Loiseau, P. (2006) Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplantation, 38, 437 444.
22. Childs, R., Clave, E., Contentin, N., Jayasekera, D., Hensel, N., Leitman, S., Read, E.J., Carter, C., Bahceci, E., Young, N.S. Barrett, A.J. (1999) Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood, 94, 3234 3240.
23. Ciceri, F., Bonini, C., Gallo-Stampino, C. Bordignon, C. (2005) Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation. Cytotherapy, 7, 144 149.
24. Cohena, Y. Nagler, A. (2003) Hematopoietic stem-cell transplantation using umbilical-cord blood. Leukemia & Lymphoma, 44, 1287 1299.
25. Collin, M., Bogunovic, M. Merad, M. (2007) DC homeostasis in hematopoietic stem cell transplantation. Cytotherapy, 9, 521 531.
26. Collins, Jr., R.H., Goldstein, S., Giralt, S., Levine, J., Porter, D., Drobyski, W., Barrett, J., Johnson, M., Kirk, A., Horowitz, M. Parker, P. (2000) Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplantation, 26, 511 516.
27. Cook, M.A., Milligan, D.W., Fegan, C.D., Darbyshire, P.J., Mahendra, P., Craddock, C.F., Moss, P.A. Briggs, D.C. (2004) The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood, 103, 1521 1526.
28. Dazzi, F. Fozza, C. (2007) Disease relapse after haematopoietic stem cell transplantation: risk factors and treatment. Best Practice & Research. Clinical Haematology, 20, 311 327.
29. Edinger, M., Hoffmann, P., Ermann, J., Drago, K., Fathman, C.G., Strober, S. Negrin, R.S. (2003) CD4(+)CD25(+) regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nature Medicine, 9, 1144 1150.
30. Falkenburg, J.H.F., Wafelman, A.R., Joosten, P., Smit, W.M., van Bergen, C.A., Boogaerts, R., Lurvink, E., van der Hoorn, M., Kluck, P., Landegent, J.E., Kluin-Nelemans, H.C., Fibbe, W.E. Willemze, R. (1999) Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood, 94, 1201 1208.
31. Falkenburg, J.H., van de Corput, L., Marijt, E.W. Willemze, R. (2003) Minor histocompatibility antigens in human stem cell transplantation. Experimental Hematology, 31, 743 751.
32. Ferrara, J.L. Reddy, P. (2006) Pathophysiology of graft-versus-host disease. Seminars in Hematology, 43, 3 10.
33. Fowler, D.H. (2006) Shared biology of GVHD and GVT effects: potential methods of separation. Critical Reviews in Oncology/Hematology, 57, 225 244.
34. Gahrton, G. (2007) Risk assessment in haematopoietic stem cell transplantation: impact of donor-recipient sex combination in allogeneic transplantation. Best Practice & Research. Clinical Haematology, 20, 219 229.
35. Galea-Lauri, J., Darling, D., Mufti, G., Harrison, P. Farzaneh, F. (2002) Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunology, Immunotherapy, 51, 299 310.
36. Hallett, W.H., Ames, E., Motarjemi, M., Barao, I., Shanker, A., Tamang, D.L., Sayers, T.J., Hudig, D. Murphy, W.J. (2008) Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. Journal of Immunology, 180, 163 170.
37. Hambach, L., Nijmeijer, B.A., Aghai, Z., Schie, M.L., Wauben, M.H., Falkenburg, J.H. Goulmy, E. (2006) Human cytotoxic T lymphocytes specific for a single minor histocompatibility antigen HA-1 are effective against human lymphoblastic leukaemia in NOD/scid mice. Leukemia, 20, 371 374.
38. Hoos, A. Levey, D.L. (2003) Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications. Expert Review of Vaccines, 2, 369 379.
39. Horowitz, M.M., Gale, R.P., Sondel, P.M., Goldman, J.M., Kersey, J., Kolb, H.J., Rimm, A.A., Ringden, O., Rozman, C. Speck, B. (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood, 75, 555 562.
40. Hsu, K.C., Keever-Taylor, C.A., Wilton, A., Pinto, C., Heller, G., Arkun, K., O'Reilly, R.J., Horowitz, M.M. Dupont, B. (2005) Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood, 105, 4878 4884.
41. Huang, X.J., Liu, D.H., Liu, K.Y., Xu, L.P., Chen, H. Han, W. (2007) Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica, 92, 414 417.
42. Hwang, W.Y., Samuel, M., Tan, D., Koh, L.P., Lim, W. Linn, Y.C. (2007) A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in adult and pediatric patients. Biology of Blood and Marrow Transplantation, 13, 444 534.
43. Keilholz, U., Letsch, A., Busse, A., Asemissen, A., Schmittel, A., Hofman, W.K., Uharek, L., Blau, I.W., Thiel, E. Scheibenbogen, C. (2006) Clinical and immune response of WT1 peptide vaccine in patients with AML. Blood, 108 (Suppl. 1 171a, abstract 567.
44. Kolb, H.J., Mittermuller, J., Clemm, C., Holler, E., Ledderose, G., Brehm, G., Heim, M. Wilmanns, W. (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood, 76, 2462 2465.
45. Kolb, H.J., Schattenberg, A., Goldman, J.M., Hertenstein, B., Jacobsen, N., Arcese, W., Ljungman, P., Ferrant, A., Verdonck, L., Niederwieser, D., van Rhee, F., Mittermueller, J., de Witte, T., Holler, E. Ansari, H. (1995) Graft-versus leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood, 86, 2041 2050.
46. Kolb, H.J., Schmid, C., Barrett, A.J. Schende, D.J. (2004) Graft-versus-leukemia reactions in allogeneic chimeras. Blood, 103, 767 776.
47. Levine, J.E., Braun, T., Penza, S.L., Beatty, P., Cornetta, K., Martino, R., Drobyski, W.R., Barrett, A.J., Porter, D.L., Giralt, S., Leis, J., Holmes, H.E., Johnson, M., Horowitz, M. Collins, Jr., R.H. (2002) Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. Journal of Clinical Oncology, 20, 405 412.
48. Lewalle, P., Delforge, A., Aoun, M., Crombez, P., de Wilde, V., Theunissen, K., Lagneaux, L., Nowak, B., Misplon, V., Bron, D. Martiat, P. (2004) Growth factors and DLI in adult haploidentical transplant: a three-step pilot study towards patient and disease status adjusted management. Blood Cells, Molecules, and Diseases, 33, 256 260.
49. Li, Z., Qiao, Y., Liu, B., Chakravarthi, P., Kulko, J.M., Bona, R.D., Fang, M., Hegde, U., Moyo, V., Tannenbaum, S.H., Ménoret, A., Gaffney, J., Glynn, L., Runowicz, C.D. Srivastava, P.K. (2005) Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clinical Cancer Research, 11, 4460 4468.
50. Litzinger, M.T., Fernando, R., Curiel, T.J., Grosenbach, D.W., Schlom, J. Palena, C. (2007) L-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood, 110, 3192 3201.
51. Locatelli, F., Zecca, M., Rondelli, R., Bonetti, F., Dini, G., Prete, A., Messina, C., Uderzo, C., Ripaldi, M., Porta, F., Giorgiani, G., Giraldi, E. Pession, A. (2000) Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood, 95, 1572 1579.
52. Lutz, C., Massenkeil, G., Nagy, M., Neuburger, S., Tamm, I., Rosen, O., Dörken, B. Arnold, R. (2008) A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 41, 805 812.
53. Machiels, J.P., van Baren, N. Marchand, M. (2002) Peptide-based cancer vaccines. Seminars in Oncology, 29, 494 502.
54. Marijt, W.A., Heemskerk, M.H., Kloosterboer, F.M., Goulmy, E., Kester, M.G., van der Hoorn, M.A., van Luxemburg-Heys, S.A., Hoogeboom, M., Mutis, T., Drijfhout, J.W., van Rood, J.J., Willemze, R. Falkenburg, J.H. (2003) Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proceedings of the National Academy of Sciences of the United States of America, 100, 2742 2747.
55. Mielke, S., Solomon, S.R. Barrett, A.J. (2005) Selective depletion strategies in allogeneic stem cell transplantation. Cytotherapy, 7, 109 115.
56. Miura, Y., Thoburn, C.J., Bright, E.C., Phelps, M.L., Shin, T., Matsui, E.C., Matsui, W.H., Arai, S., Fuchs, E.J., Vogelsang, G.B., Jones, R.J. Hess, A.D. (2004) Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood, 104, 2187 2193.
57. Mohty, M., Avinens, O., Faucher, C., Viens, P., Blaise, D. Eliaou, J.F. (2007) Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. Haematologica, 92, 1004 1006.
58. Montero, A., Savani, B.N., Shenoy, A., Read, E.J., Carter, C.S., Leitman, S.F., Mielke, S., Rezvani, K., Childs, R. Barrett, A.J. (2006) T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome. Biology of Blood and Marrow Transplantation, 12, 1318 1323.
59. Morita, S., Oka, Y., Tsuboi, A., Kawakami, M., Maruno, M., Izumoto, S., Osaki, T., Taguchi, T., Ueda, T., Myoui, A., Nishida, S., Shirakata, T., Ohno, S., Oji, Y., Aozasa, K., Hatazawa, J., Udaka, K., Yoshikawa, H., Yoshimine, T., Noguchi, S., Kawase, I., Nakatsuka, S., Sugiyama, H. Sakamoto, J. (2006) A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Japanese Journal of Clinical Oncology, 36, 231 236.
60. Nadal, E., Garin, M., Kaeda, J., Apperley, J., Lechler, R. Dazzi, F. (2007) Increased frequencies of CD4(+)CD25(high) T(regs) correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia, 21, 472 479.
61. Nakamura, R., Bahceci, E., Read, E.J., Leitman, S.F., Carter, C.S., Childs, R., Dunbar, C.E., Gress, R., Altemus, R., Young, N.S. Barrett, A.J. (2001) Transplant dose of CD34(+) and CD3(+) cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back. British Journal of Haematology, 115, 95 10.
62. Olavarria, E., Siddique, S., Griffiths, M.J., Avery, S., Byrne, J.L., Piper, K.P., Lennard, A.L., Pallan, L., Arrazi, J.M., Perz, J.B., O'Shea, D., Goldman, J.M., Apperley, J.F. Craddock, C.F. (2007) Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood, 110, 4614 4617.
63. Papadopoulos, E.B., Carabasi, M.H., Castro-Malaspina, H., Childs, B.H., Mackinnon, S., Boulad, F., Gillio, A.P., Kernan, N.A., Small, T.N., Szabolcs, P., Taylor, J., Yahalom, J., Collins, N.H., Bleau, S.A., Black, P.M., Heller, G., O'Reilly, R.J. Young, J.W. (1998) T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood, 91, 1083 1090.
64. Peggs, K.S., Thomson, K., Hart, D.P., Geary, J., Morris, E.C., Yong, K., Goldstone, A.H., Linch, D.C. Mackinnon, S. (2004) Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood, 103, 1548 1556.
65. Pollyea, D.A., Artz, A.S., Stock, W., Daugherty, C., Godley, L., Odenike, O.M., Rich, E., Smith, S.M., Zimmerman, T., Zhang, Y., Huo, D., Larson, R. van Besien, K. (2007) Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 40, 1027 1032.
66. Qazilbash, M.H., Wieder, E.D., Thall, P.F., Champlin, R.K. Molldrem, J. (2007) PR1 peptide vaccine-induced immune response is associated with better event-free survival in patients with myeloid leukemia. Blood, 110 (Suppl. 1 90a.
67. Rapoport, A.P., Stadtmauer, E.A., Aqui, N., Badros, A., Cotte, J., Chrisley, L., Veloso, E., Zheng, Z., Westphal, S., Mair, R., Chi, N., Ratterree, B., Pochran, M.F., Natt, S., Hinkle, J., Sickles, C., Sohal, A., Ruehle, K., Lynch, C., Zhang, L., Porter, D.L., Luger, S., Guo, C., Fang, H.B., Blackwelder, W., Hankey, K., Mann, D., Edelman, R., Frasch, C., Levine, B.L., Cross, A. June, C.H. (2005) Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nature Medicine, 11, 1230 1237.
68. Reddy, V., Winer, A.G., Eksioglu, E., Meier-Kriesche, H.U., Schold, J.D. Wingard, J.R. (2005) Interleukin 12 is associated with reduced relapse without increased incidence of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 11, 1014 1021.
69. Rezvani, K., Grube, M., Brenchley, J.M., Sconocchia, G., Fujiwara, H., Price, D.A., Gostick, E., Yamada, K., Melenhorst, J., Childs, R., Hensel, N., Douek, D.C. Barrett, A.J. (2003) Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood, 102, 2892 2900.
70. Rezvani, K., Mielke, S., Ahmadzadeh, M., Kilical, Y., Savani, B.N., Zeilah, J., Keyvanfar, K., Montero, A., Hensel, N., Kurlander, R. Barrett, A.J. (2006) High donor Foxp3-positive regulatory T-cell (TREG) content is associated with a low risk of GVHD following HLA-matched allogeneic stem cell transplantation (SCT). Blood, 108, 1291 1297.
71. Rezvani, K., Yong, A.S., Savani, B.N., Mielke, S., Keyvanfar, K., Gostick, E., Price, D.A., Douek, D.C. Barrett, A.J. (2007a) Graft-versus- leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood, 110, 1924 1932.
72. Rezvani, K., Price, D.A., Brenchley, J.M., Kilical, Y., Gostick, E., Sconocchia, G., Hansmann, K., Kurlander, R., Douek, D.C. Barrett, A.J. (2007b) Transfer of PR1-specific T-cell clones from donor to recipient by stem cell transplantation and association with GvL activity. Cytotherapy, 9, 245 251.
73. Rezvani, K., Yong, A.S., Mielke, S., Savani, B.N., Musse, L., Superata, J., Jafarpour, B., Boss, C. Barrett, A.J. (2008) Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood, 111, 236 242.
74. Rice, J., Dunn, S., Piper, K., Buchan, S.L., Moss, P.A. Stevenson, F.K. (2006) DNA fusion vaccines induce epitope-specific cytotoxic CD8(+) T cells against human leukemia-associated minor histocompatibility antigens. Cancer Research, 66, 5436 5442.
75. Riddell, S.R., Bleakley, M., Nishida, T., Berger, C. Warren, E.H. (2006) Adoptive transfer of allogeneic antigen-specific T cells. Biology of Blood and Marrow Transplantation, 12 (Suppl. 1 9 12.
76. Ringden, O., Barrett, A.J., Zhang, M.J., Loberiza, F.R., Bolwell, B.J., Cairo, M.S., Gale, R.P., Hale, G.A., Litzow, M.R., Martino, R., Russell, J.A., Tiberghien, P., Urbano-Ispizua, A. Horowitz, M.M. (2003) Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. British Journal of Haematology, 121, 874 885.
77. Ringhoffer, M., Harsdorf, S., Schmitt, M., Wiesneth, M., Zenz, T., Stilgenbauer, S., Greiner, J., Döhner, K., Marx, M., Döhner, H. Bunjes, D. (2007) Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse. British Journal of Haematology, 136, 127 130.
78. Rosenblatt, J. Avigan, D. (2006) Can leukemia-derived dendritic cells generate antileukemia immunity? Expert Review of Vaccines, 5, 467 472.
79. Ruggeri, L., Capanni, M., Casucci, M., Volpi, I., Tosti, A., Perruccio, K., Urbani, E., Negrin, R.S., Martelli, M.F. Velardi, A. (1999) Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood, 94, 333 339.
80. Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W.D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., Martelli, M.F. Velardi, A. (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science, 295, 2097 2100.
81. Russell, N.H., Byrne, J.L., Faulkner, R.D., Gilyead, M., Das-Gupta, E.P. Haynes, A.P. (2005) Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplantation, 36, 437 441.
82. Savani, B.N., Montero, A., Kurlander, R., Childs, R., Hensel, N. Barrett, A.J. (2005) Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplantation, 36, 1009 1015.
83. Savani, B.N., Mielke, S., Adams, S., Uribe, M., Rezvani, K., Yong, A.S., Zeilah, J., Kurlander, R., Srinivasan, R., Childs, R., Hensel, N. Barrett, A.J. (2007) Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia, 21, 2145 2152.
84. Scheibenbogen, C., Letsch, A., Thiel, E., Schmittel, A., Mailaender, V., Baerwolf, S., Nagorsen, D. Keilholz, U. (2002) CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood, 100, 2132 2137.
85. Schmid, C., Schleuning, M., Schwerdtfeger, R., Hertenstein, B., Mischak-Weissinger, E., Bunjes, D., Harsdorf, S.V., Scheid, C., Holtick, U., Greinix, H., Keil, F., Schneider, B., Sandherr, M., Bug, G., Tischer, J., Ledderose, G., Hallek, M., Hiddemann, W. Kolb, H.J. (2006) Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood, 108, 1092 1099.
86. Schmid, C., Labopin, M., Nagler, A., Bornhäuser, M., Finke, J., Fassas, A., Volin, L., Gürman, G., Maertens, J., Bordigoni, P., Holler, E., Ehninger, G., Polge, E., Gorin, N.C., Kolb, H.J. Rocha, V. (2007) EBMT Acute Leukemia Working Party. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. Journal of Clinical Oncology, 25, 4938 4945.
87. Schumacher, L.Y., Vo, D.D., Garban, H.J., Comin-Anduix, B., Owens, S.K., Dissette, V.B., Glaspy, J.A., McBride, W.H., Bonavida, B., Economou, J.S. Ribas, A. (2006) Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). Journal of Immunology, 176, 4757 4765.
88. Shlomchik, W.D., Couzens, M.S. Tang, C.B. (1999) Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science, 285, 412 415.
89. Sloand, E., Childs, R.W., Solomon, S., Greene, A., Young, N.S. Barrett, A.J. (2003) The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia. Bone Marrow Transplantation, 32, 897 901.
90. Solomon, S.R., Mielke, S., Savani, B.N., Montero, A., Wisch, L., Childs, R., Hensel, N., Schindler, J., Ghetie, V., Leitman, S.F., Mai, T., Carter, C.S., Kurlander, R., Read, E.J., Vitetta, E.S. Barrett, A.J. (2005) Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood, 106, 1123 1129.
91. Stan, R., Wolchok, J.D. Cohen, A.D. (2006) DNA vaccines against cancer. Hematology/Oncology Clinics of North America, 20, 613 636.
92. Taylor, P.A., Lees, C.J. Blazar, B.R. (2002) The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood, 99, 3493 3499.
93. Thomas, S., Xue, S.A., Cesco-Gaspere, M., San José, E., Hart, D.P., Wong, V., Debets, R., Alarcon, B., Morris, E. Stauss, H.J. (2007) Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells. Journal of Immunology, 179, 5803 5810.
94. Trenado, A., Charlotte, F. Fisson, S. (2003) Recipient-type specific CD4+ CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. Journal of Clinical Investigation, 112, 1688 1696.
95. Urbano-Ispizua, A. (2007) Risk assessment in haematopoietic stem cell transplantation: stem cell source. Best Practice & Research. Clinical Haematology, 20, 265 280.
96. Verheyden, S., Schots, R., Duquet, W. Demanet, C. (2005) A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia, 19, 1446 1451.
97. Weiden, P.L., Flournoy, N., Thomas, E.D., Prentice, R., Fefer, A., Buckner, C.D. Storb, R. (1979) Antileukemic effects of graft-versus-host disease in human recipients of allogeneic marrow grafts. New England Journal of Medicine, 300, 1068 1071.
98. Zeng, Y., Feng, H., Graner, M.W. Katsanis, E. (2003) Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood, 101, 4485 4491.
99. Zhang, H., Chua, K.S., Guimond, M., Kapoor, V., Brown, M.V., Fleisher, T.A., Long, L.M., Bernstein, D., Hill, B.J., Douek, D.C., Berzofsky, J.A., Carter, C.S., Read, E.J., Helman, L.J. Mackall, C.L. (2005) Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+ CD25+ regulatory T cells. Nature Medicine, 11, 1238 1243.